Malcolm Foster, MD
Interventional Cardiology · Knoxville, TNNPI 1861482556
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 23.1%. Among interventional cardiology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,204 payments — averaging $343.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$95K
- Shockwave Medical, Inc$86K
- Penumbra, Inc.$51K
- Amgen$40K
- Amarin Pharma, Inc.$38K
- Johnson & Johnson$29K
- plus $74K from 54 others
Across 637 payments — averaging $2355.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$273K
- CSL Behring$254K
- American Regent$213K
- Janssen Research & Development, LLC$130K
- Novartis$127K
- Angiodynamics, Inc.$90K
- plus $413K from 20 others
What the payments were for
- Royalty or licence$2,2201%
- Consulting fees$106,93826%
- Speaking & faculty fees$230,30356%
- Travel & lodging$37,1629%
- Food & beverage$35,8619%
- Education$1750%
- Ownership interest$6300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$84,275
- Repatha$38,028
- Vascepa$37,342
- Indigo System$35,857
- XARELTO$28,177
- XACT$27,723
- OPTIS$19,450
- BRILINTA$17,390
- NEXLIZET$15,990
- NEXLETOL$15,990
- AMPLATZER TALISMAN$15,214
- ACCULINK$14,821
- EMBOSHIELD NAV6$10,480
- AlphaVac$10,027
- Indigo$9,308
- AngioVac$8,758
- RUBY Coil$6,844
- Xience V coronary stent system$2,500
- AccuCinch$2,240
- Ostial Pro Stent Position Sys$1,943
How this compares
$413,287 in reported general payments places this provider in the 95th percentile of 207 interventional cardiology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 284 | $368,139 |
| Repatha SureclickEvolocumab | 234 | $225,605 |
| XareltoRivaroxaban | 154 | $179,497 |
| EntrestoSacubitril/Valsartan | 79 | $75,804 |
| BrilintaTicagrelor | 79 | $64,612 |
| JardianceEmpagliflozin | 24 | $27,009 |
| Praluent PenAlirocumab | 32 | $19,265 |
| VascepaIcosapent Ethyl | 17 | $13,375 |
| FarxigaDapagliflozin Propanediol | 15 | $10,640 |
| Dofetilide | 30 | $8,240 |
| Prasugrel Hcl | 101 | $5,512 |
| ClopidogrelClopidogrel Bisulfate | 478 | $4,738 |
| Rosuvastatin Calcium | 340 | $4,439 |
| Ezetimibe | 182 | $3,397 |
| Losartan Potassium | 203 | $3,217 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $528 | $368,139284 claims |
| Johnson & JohnsonXarelto | $29,286 | $179,497154 claims |
| NovartisEntresto | $1,148 | $75,80479 claims |
| AstraZenecaBrilinta, Farxiga | $18,524 | $75,25294 claims |
| Boehringer IngelheimJardiance | $193 | $27,00924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 207 interventional cardiology providers in Tennessee.
Other interventional cardiology in Knoxville
- Ayaz RahmanKnoxville$251K
- Sara NegrottoKnoxville$114K
- Stuart BreseeKnoxville$112K
- Rachel GoodwinKnoxville$74K
- Joshua ToddKnoxville$45K
- Morgan RandallKnoxville$29K
- Briana CostelloKnoxville$28K
- Barry MichelsonKnoxville$17K
- Jimmy KerriganNashville$644K
- Kashish GoelNashville$558K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.